Objective To explore differences in antithrombotic management of patients with acutely symptomatic carotid stenosis ("hot carotid") awaiting revascularization with endarterectomy or stenting (CEA/CAS).
Carotid atherosclerosis accounts for 15%-20% of ischemic strokes and TIA. [1] [2] [3] In a pooled analysis of 3 prospective studies (2 registries and 1 population based), about 24% of patients with symptomatic 50%-99% carotid stenosis had ipsilateral recurrent ischemic events in the first 14 days pre-revascularization. 4 Such patients accounted for 37% of recurrent strokes within 7 days of the initial event in a meta-analysis of population-based studies. 5 Revascularization of symptomatic carotid stenosis via endarterectomy (CEA) is therefore time sensitive-most beneficial within 2 weeks of the last eventwith stenting (CAS) being an alternative strategy. 6, 7 This urgency confronts the neurologist treating patients with a "hot carotid," defined pragmatically as a recent stroke/TIA (within hours-days of symptom onset) thought to be etiologically related to carotid stenosis. 8 The optimal antithrombotic regimen for patients with a hot carotid is unknown, particularly as they await CEA/CAS, the key trade-off being between optimizing recurrent ischemic stroke prevention vs minimizing hemorrhagic risk. The Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trials have shown a lower risk of major ischemic events with dual antiplatelet therapy (DAPT) using clopidogrel plus aspirin vs aspirin alone for 21 and 90 days, respectively, in a broad population with minor stroke/TIA, with most recurrent events occurring within 1 week. 9, 10 However, there was a greater risk of major hemorrhage with 90 days of DAPT in the POINT trial; a meta-analysis of CHANCE and POINT concluded that the benefit of DAPT appeared confined to the first 21 days. 11 Patients with hot carotids were, however, excluded from these trials by design. Trials of intracranial atherosclerosis (ICAS) have shown that warfarin carries greater harm and no benefit over aspirin 12 and that aggressive medical management with DAPT, statin, and blood pressure control confers a low risk of recurrent events. 12, 13 A subgroup analysis of CHANCE found that the effects of DAPT vs aspirin alone in reducing stroke recurrence risk or leading to hemorrhage were not significantly different between patients with TIA/stroke with/without ICAS. 14 The generalizability of these findings to patients with cervical carotid atherosclerosis is uncertain. A recent meta-analysis 15 of 7 observational studies and 3 randomizedcontrolled trials (RCTs) [16] [17] [18] comparing outcomes of single vs DAPT in CEA/CAS found that DAPT reduced the risk of TIA (not stroke) in patients undergoing CAS, but was associated with increased bleeding in those undergoing CEA. However, the overall quality of evidence was low to moderate. Uncertainty is heightened when one considers using alternative antiplatelet agents such as ticlopidine 17 or ticagrelor, 19 or combining or substituting with pre-/perioperative anticoagulation (heparin, warfarin, or direct oral anticoagulants), 20 all carrying their own balance of risks vs benefits and often not specifically studied in the hot carotid setting. Decision making is further complicated when intraluminal thrombi (ILT) are seen on vessel imaging. 21, 22 Given these uncertainties, we recently interviewed experts from 3 continents regarding how to manage patients with a hot carotid awaiting CEA/CAS. 23 The experts preferred CT angiography (CTA) for carotid imaging and CEA for revascularization. While noting the potential benefit of DAPT in preventing recurrent events, they recognized varying preferences of surgeons in this regard, with patients sometimes reverting to aspirin perioperatively. They generally favored anticoagulation plus aspirin in patients with ILT but differed on the type and duration of anticoagulation. A more quantitative understanding of how clinicians differ in their approach to hot carotids can help inform the design of future RCTs by highlighting enduring areas of uncertainty. Therefore, we explored practice differences in hot carotid management using a worldwide electronic survey.
Methods

Survey
The survey was launched by the Practice Current section of Neurology® Clinical Practice (neurology.org/collection/ practice_current). We used an electronic survey with 10 clinical and 7 demographic questions (appendix e-1, links. lww.com/CPJ/A166). The clinical questions pertained to a representative case of a 65-year-old patient presenting with acute-onset right-sided weakness lasting several hours, found to have 80% left-sided extracranial internal carotid artery stenosis. After appropriate hyperacute management, a plan is made for revascularization (CEA/CAS) within the next week, and a statin is started. Respondents were asked about (1) the preferred imaging modality for evaluating the presence and extent of carotid stenosis, (2) preferred revascularization procedure, (3) typical wait time for revascularization, (4) typically favored antithrombotic agent(s), (5) favored agent(s) if the patient was already on low-dose aspirin, (6) favored agent(s) in the presence of ILT, (7) clinical and (8) imaging features that would increase their enthusiasm for additional antithrombotic agents beyond single antiplatelet, and (9) clinical and (10) imaging features that would decrease their enthusiasm for additional agents.
Demographic questions included population treated (adults/ children/both), years in practice, work setting, training level, and practice location. The survey was available online and was anonymous. Participation did not require membership in the American Academy of Neurology (AAN) or subscription to AAN journals. No compensation was offered. A link to the questionnaire was available in the Neurology® journal web pages, in online ads and the print version of the journals, and in the Practice Current dedicated web page. The survey was also advertised by the AAN and Neurology® journals via social media. Individual Internet protocol address was collected to ensure response authenticity. We opened the survey from September 6, 2018, to November 10, 2019, and all responses collected were included in the analysis.
Statistical analysis
Besides summary statistics, the frequency of responses for each question/scenario was compared for different groups, focusing on (1) preferred revascularization strategy (CEA vs CAS) (2) typical CEA/CAS wait time (2-3 days, 3-7 days, and >7 days), (3) years in practice (trainee, <10-year experience, and >10-year experience), and (4) practice location (United States/ Canada, Latin America, Europe, Asia, Africa, and Australia/ Oceania). Specifically, we examined the proportion of respondents by years in practice and location who preferred (1) CTA over other imaging modalities and (2) CEA over CAS. We then examined the proportion of respondents by preferred revascularization strategy, years in practice, and location who reported wait times >7 days. We then examined the proportion of respondents in all 4 groupings of interest who (1) chose ≥2 antithrombotic agents in each of the 3 hot carotid scenarios (general presentation, if the patient was already on single antiplatelet therapy, or if there was ILT), (2) chose a regimen containing the most popular agent in each of the scenarios, and (3) identified each clinical/imaging factor as increasing/ decreasing their enthusiasm for using additional agents beyond single antiplatelet and statin therapy.
Whereas low-dose aspirin was specified in our survey as 75-81 mg and high-dose aspirin as 160-325 mg, several respondents specified 100 mg of aspirin as their preferred antithrombotic (on selecting the "Other" option); therefore, we expanded our definition of low-dose aspirin to include 75-100 mg for our analyses.
For univariable analysis, we used the Fisher exact test. After identifying differences between the groups with p < 0.05 on univariable analysis, multivariable logistic regression was performed to adjust for all confounding variables. Statistical significance was set at 2-sided p < 0.050. Analyses were performed using STATA 13.1.
Standard protocol approvals, registrations, and patient consents
The study was certified as exempt from review by the Children's National Medical Center Institutional Review Board.
Data availability
Requests for access to the data used in this article will be considered by the corresponding author.
Results
We received 668 responses from 71 countries, of which 561 (84.0%) were complete (respondent characteristics in table 1). Most respondents preferred CTA to determine significant carotid atherosclerosis (table 2) . Of note, 46.9% preferred to use more than 1 imaging modality, the most popular combination being ultrasound and CTA (32.8%). Respondents outside the United States/Canada were less likely to favor CTA, although it remained the most popular option overall in each region (e.g., Latin America, adjusted odds ratio [aOR] [adjusted for years in practice and region]: 0.35, 95% confidence interval 0.19-0.64, p = 0.001, table e-1, links.lww.com/CPJ/A165). CEA was favored over CAS by 69.1% of respondents (table 3) . Respondents outside the United States/Canada were less likely to favor CEA-although it remained the more popular choice in all regions-with the discrepancy being greatest among respondents from Asia (53.7% preferring CEA vs 83.7% in the United States/Canada, p = 0.001, table e-2, links.lww.com/CPJ/A165). Respondents reported longer wait times for CAS (e.g., >7 days: 45.7% for CAS vs 31.8% for CEA, p < 0.001) with respondents outside the United States/Canada more likely to report wait times >7 days in multivariable analyses (e.g., Asia aOR [adjusted for preferred revascularization, years in practice, region]: 5.35, 2.99-9.59, p < 0.001, table e-3, links.lww.com/CPJ/A165).
When asked about preferred antithrombotic agent(s) for a patient with a hot carotid awaiting revascularization, 561 (88.5%) proposed a regimen containing aspirin (low dose/75-100 mg or high dose/160-325 mg). Most respondents preferred using a single agent (54.4%, table 4), the most common choice being high-dose aspirin (25.6%). Of note, 41.3% preferred dual therapy, and 3.6% preferred triple therapy; the most common combination was low-dose aspirin with clopidogrel (22.2%), although a wide variety of regimens were chosen ( When asked what clinical and imaging factors would increase their enthusiasm to use additional antithrombotic agents beyond single angle-platelet therapy, the most favored clinical factors were the patient having multiple TIAs in that carotid territory, already being on an antithrombotic agent, and awaiting CAS rather vs CEA (table 5) . The most popular imaging factors were ILT, ulcerated plaque, and microembolic signals on transcranial Doppler (TCD). On multivariable analysis, respondents who preferred CAS more often identified the decision to pursue CAS (vs CEA), echolucent plaque, and atherosclerotic disease in other arteries as increasing their enthusiasm for additional agents (table e-11, links.lww.com/CPJ/ A165). Respondents reporting revascularization wait times >7 days more often identified being on an antithrombotic premorbidly as increasing their enthusiasm for additional agents, but less often identified stenting as a relevant factor. Respondents reporting more years of independent practice more often identified multiple TIAs in the same territory, microembolic signals on TCD, echolucent plaque, ILT, and tandem intracranial disease as relevant factors.
When asked what clinical and imaging factors would decrease their enthusiasm for additional antithrombotic agents beyond single angle-platelet therapy, the most favored clinical factors were receiving IV alteplase (although we specified this was >24 hours prior), awaiting CEA and not CAS, and CEA/CAS anticipated to occur within 2 days (table 6). The most favored imaging factors were microbleeds on MRI (56.3%), lesser degree of stenosis (33.9%), and larger vs smaller infarct on imaging (33.7%). On multivariable analysis, respondents preferring CAS were more likely to identify female sex and decision to pursue CEA (vs CAS) as decreasing their enthusiasm for additional agents (table e-12, links.lww.com/CPJ/ A165). Respondents reporting more years of independent practice more often identified female sex, isolated ocular CTA and DSA
(3.4)
MRA and DSA 6 (0.9)
Abbreviations: CTA = CT angiography; DSA = digital subtraction angiography; MRA = MR angiography.
symptoms, smooth stenosis, and larger infarct as decreasing their enthusiasm for additional agents.
Results of testing for internal consistency
On testing for internal consistency in responses, 73.7% of respondents who preferred CAS, and identified CAS (vs CEA) as increasing their enthusiasm for using more than just single antiplatelet and statin therapy, also chose ≥2 antithrombotic agents in ≥1 scenario. Of note, 69.7% of respondents who reported wait times of 2-3 days and identified wait times of 2 days as decreasing their enthusiasm for additional agents chose only 1 agent on all scenarios, as did 53.5% of respondents who preferred CEA and identified the decision to pursue CEA as lowering their enthusiasm for additional agents.
However, only 35.3% of respondents who identified already being on an antithrombotic agent as increasing their enthusiasm for aggressive antithrombotic therapy, and 34.0% of respondents who identified ILT as doing the same, actually chose ≥2 agents for the scenarios with the patient on aspirin premorbidly and with associated ILT, respectively.
Discussion
Practice patterns can become established in medicine even with inadequate evidence. Identifying areas of agreement and disagreement may help clinicians critically examine and refine their own practice patterns, in addition to informing further studies in this area. In this large Practice Current worldwide survey of neurologists, we identified considerable heterogeneity in the medical management of hot carotids. Our results have implications for the design of future RCTs.
First, our findings that CTA (potentially combined with ultrasound) is the preferred method of evaluating carotid stenosis and that CEA is the preferred revascularization strategy for the vast majority of respondents offer a common ground for building further strategies for hot carotid management. In such an environment, a study of periprocedural antithrombotic management that requires MRI-based evaluation or only examines patients awaiting CAS may struggle to gain traction. CTA would suffice to identify ulcerated plaque-identified by the majority of respondents as increasing their enthusiasm for more aggressive antithrombotic therapy-which could be incorporated into studies of risk-stratified therapy. However, CT would not detect microbleeds, identified by the majority of respondents as decreasing their enthusiasm for additional antithrombotic agents, although only 16.5% reported using MRI.
Second, the choice of the revascularization procedure appears to influence antithrombotic therapy because respondents favoring CAS more often chose multiple antithrombotic agents. Respondents reported longer wait times for CAS vs CEA, which may have encouraged more aggressive antithrombotic therapy, but wait times had an inconsistent association with antithrombotic choices in our study. The preferred antithrombotic therapy may be driven more by what is perceived as appropriate preparation for the procedure than by what is considered best medical management for stroke prevention. The observed difference may also relate to greater perceived harm of more aggressive antithrombotic regimens with CEA, 24, 25 greater perceived thromboembolic risk with CAS, 7 or challenges with accommodating surgeon preferences in CEA. The rationale driving these clinical decisions merits further investigation, perhaps by in-depth qualitative interviews.
Third, our results demonstrate that despite the high upfront risk of recurrent events and the rise of short-term DAPT for secondary prevention, monotherapy is still preferred by most All percentages in the first column add to 100%, whereas the remaining percentages in each row add to 100%.
The choice of the revascularization procedure appears to influence antithrombotic therapy because respondents favoring CAS more often chose multiple antithrombotic agents.
clinicians managing a hot carotid, even in the setting of premorbid antiplatelet therapy or ILT. This was despite ILT being identified by the majority of respondents as a factor encouraging them to use more than just single antiplatelet therapy. The most favored monotherapy was aspirin, the benefit of which is well established for secondary prevention, 26 but respondents were split between using low dose (75-100 mg) or high dose (160-325 mg) formulations. This variable dosing has implications for the relative safety and efficacy of aspirin in patients with different body sizes and is itself an avenue for further study. 27 When dual therapy was chosen, the most favored combination was low-dose aspirin plus clopidogrel (DAPT), with high-dose aspirin favored if the patient was already on aspirin premorbidly. This implies that future RCTs comparing antithrombotic strategies in patients with hot carotids will likely need to include high-dose aspirin or DAPT as a comparator arm to receive buy-in from physician stakeholders. Fourth, our results highlight key regional variations in hot carotid management, which merit being addressed within the design of multicenter RCTs and/or quality improvement initiatives. Such differences included a greater preference for CAS among respondents from Asia (although CEA was still favored by a majority) and longer wait times for revascularization reported by those outside the United States/Canada. Given the urgency of carotid revascularization with symptomatic stenosis, improving wait times should be an important worldwide priority. [28] [29] [30] Key regional differences in antithrombotic regimens included respondents from Europe less commonly choosing multiple agents if already on aspirin, those from Asia more often favoring multiple agents, vs those from the United States/Canada preferentially choosing heparin-containing regimens in the setting of ILT. Accommodating and/or accounting for these preferences can help RCTs optimize enrollment or anticipate differential enrollment rates in different regions, depending on the regimens permitted.
Although our analysis has several strengths, including a large worldwide sample, representation of various practice settings and levels of experience, and inclusion of some checks of internal consistency of the responses, there are important shortcomings. First, we could not represent the full spectrum of hot carotid presentations and treatment conundrums needed for more granular analyses of physician decision making. However, we decided to use 3 brief scenarios to maximize survey completion and included additional questions regarding clinical/ imaging factors that would influence the respondents' choices to further understand their rationale. Even so, we could not determine the influence that factors such as the patient's ethnicity, comorbidities, neurologic findings, functional status, acute stroke treatments received, the method of determination of the degree of carotid stenosis, or genetic polymorphisms (such as in CYP2C19) may have on respondents' antithrombotic choices. For instance, around 30% of whites and 50%-60% of Asians with stroke/TIA are carriers of the CYP2C19 loss-of-function allele, which may reduce the efficacy of clopidogrel. 31 Second, we cannot be confident whether respondents chose an option because they thought it was the best for the patient or because they felt it would be most Our results highlight key regional variations in hot carotid management, which merit being addressed within the design of multicenter RCTs and/or quality improvement initiatives.
feasible within their practice. Third, because we did not contact respondents, we could not verify the veracity of respondents' qualifications (such as being a neurologist) or baseline characteristics. However, by not limiting respondents to our network, we were able to capture a greater diversity of respondents. That being said, parts of the world with fewer respondents are at high risk of not being representative of regional practice, instead reflecting the practice of a select few. Fourth, our exploratory analysis was not adjusted for multiple comparisons, resulting in a risk of type 1 errors. Fifth, we did not include transcarotid artery revascularization in this survey; this approach is gaining acceptance in the vascular surgery community, and it is unknown how its adoption might affect choices of antithrombotic management. 32 We also did not examine the role of best medical management vs revascularization in cases with more intermediate degrees of stenosis or for poor procedural candidates; practice variations in this regard merit exploration in future work. Sixth, given the heterogeneity of the hot carotid patient population-with some patients potentially better suited for CAS vs CEA, some having ILT, etc.-a "one size fits all" approach for antithrombotic therapy may be impractical.
In conclusion, while providing guidance on areas of relative agreement on hot carotid management, the areas of equipoise identified by our study can help inform the design of future RCTs. Such RCTs will need to be guided by an understanding of the practice patterns and attitudes of physician stakeholders, including regional variations, to successfully enroll patients and help resolve practical uncertainties.
Study funding
This study was funded by a Heart and Stroke Foundation Professorship held by Dr. Bijoy K. Menon, the senior study investigator.
Disclosure
A. Ganesh is a member of the editorial team of Neurology; has received speaker honoraria from The Meritas Seminar Series, 
